- Algernon Pharmaceuticals has met the co-primary endpoint in its Phase 2 proof of concept study evaluating NP-120 for the treatment of idiopathic pulmonary fibrosis and chronic cough
- Based on the positive data, the company plans to file a pre-IND application with the U.S. FDA for a Phase 2b IPF study
- Christopher J. Moreau, CEO of Algernon Pharmaceuticals, sat down with Sabrina Cuthbert to discuss the update
- Algernon is a drug re-purposing company that investigates safe, already approved drugs, and naturally occurring compounds, for new disease applications
- Algernon Pharmaceuticals Inc. (AGN) opened trading at C$3.17 per share
Algernon Pharmaceuticals (AGN) has met the co-primary endpoint in its Phase 2 proof of concept study evaluating NP-120 (Ifenprodil).
Ifenprodil is being evaluated for the potential treatment of idiopathic pulmonary fibrosis (“IPF”) and chronic cough.
Based on the positive data, the company plans to file a pre-IND application with the U.S. FDA for a Phase 2b IPF study. The Phase 2b study will also have multiple arms, multiple doses, would be placebo controlled and would be double blinded and randomized.
For chronic cough, Algernon has already filed a pre-IND application with the U.S. FDA and has announced that it has received positive feedback.
Christopher J. Moreau, CEO of Algernon Pharmaceuticals, sat down with Sabrina Cuthbert to discuss the update.
Algernon is a drug re-purposing company that investigates safe, already approved drugs for new disease applications.
Algernon Pharmaceuticals Inc. (AGN) opened trading at C$3.17.
